title: Comparative antimicrobial activity of ceftibuten against multiply-resistant microorganisms from Belgium.
abstract: To study the activity of ceftibuten, we obtained multiply-resistant isolates from approximately 20 hospitals in Belgium. Against Enterobacteriaceae, all of the tested comparative compounds were more active than cefaclor, and ceftibuten and tigemonam were the most active of the agents tested. Ceftibuten MIC50s were less than or equal to 1 microgram/ml for most enteric bacilli species and 85% of strains were susceptible (less than or equal to 8 micrograms/ml). This level of activity compared favorably to that recorded for cefaclor (less than or equal to 8 micrograms/ml), cefetamet (less than or equal to 4 micrograms/ml), and cefteram (less than or equal to 1 microgram/ml), that is, 37%, 69%, and 59%, respectively. Ceftibuten, cefetamet, cefteram, and tigemonam were highly active against isolates of Haemophilus influenzae and Neisseria gonorrhoeae. None of the comparative agents were as active as cefaclor against staphylococcal isolates. Against streptococci, cefteram was the most active, and tigemonam the least active of the agents. The MIC90s of ceftibuten for strains of Streptococcus pneumoniae and Streptococcus pyogenes were 2 micrograms/ml and 0.5 microgram/ml, respectively. Strains of Streptococcus agalactiae were resistant to both ceftibuten and tigemonam; cefaclor and cefteram inhibited 100% of isolates of this species. Strains of Enterococcus faecalis and Pseudomonas aeruginosa were consistently resistant to all of the compounds. Overall, ceftibuten exhibited potent activity against many multiply-resistant clinical isolates.
authors.affiliation: Diagnostic Bacteriology Laboratory, University Hospital St. Rafael, University of Leuven, Belgium.
authors.forename: L
authors.initials: L
authors.lastname: Verbist
authors.forename: J
authors.initials: J
authors.lastname: Jacobs
authors.forename: K
authors.initials: K
authors.lastname: Hens
mesh_terms: D001419:Bacteria / Q000187:drug effects*; D001530:Belgium; D002433:Cefaclor / Q000494:pharmacology; D015281:Cefmenoxime / Q000031:analogs & derivatives / Q000494:pharmacology; D000077722:Ceftibuten; D015296:Ceftizoxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D008997:Monobactams / Q000494:pharmacology; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
chemical_list: D002511:Cephalosporins; D008997:Monobactams; C047444:cefetamet; D002433:Cefaclor; C049493:cefteram; C052020:tigemonam; D015296:Ceftizoxime; D000077722:Ceftibuten; D015281:Cefmenoxime